May 11, 2020 / 12:41 PM / 24 days ago

BRIEF-Evelo Biosciences Reports Q1 Financial Results

May 11 (Reuters) - Evelo Biosciences Inc:

* EVELO BIOSCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

* TO CONTINUE ENROLLMENT IN TRIPLE-NEGATIVE BREAST CANCER ARM OF ONGOING PHASE 1/2 TRIAL OF EDP1503

* EVELO BIOSCIENCES - SELECTED ENTERIC CAPSULE FORMULATION OF EDP1815 FOR PHASE 2 DOSE RANGING TRIAL IN PSORIASIS; TRIAL INITIATION NOW EXPECTED IN Q3

* SELECTED ENTERIC CAPSULE FORMULATION OF EDP1815 FOR PHASE 2 DOSE RANGING TRIAL IN PSORIASIS, SEES INTERIM DATA IN MID-2021

* Q1 LOSS PER SHARE $0.71

* Q1 EARNINGS PER SHARE VIEW $-0.73 — REFINITIV IBES DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below